Puricore Share Discussion Threads

[5pongebob] 11/11/2009 14:09

bengo......just a matter of time before that last rns came out mate...........

[topinfo] 11/11/2009 14:09

DJ PuriCore Results For Vashe Wound Therapy Show Promise

LONDON (Dow Jones)--PuriCore PLC (PURI.LN), a life sciences company focused on developing and commercialising proprietary solutions, said Wednesday that a clinical trial for Vashe Wound Therapy in the post-operative care of split-thickness skin grafts for burn injuries showed that the substance is effective as the control, 5% Sulfamylon solution (mafenide acetate, U.S.P), a synthetic antimicrobial agent, in the post-operative care of grafts for burns and potentially provides greater pain control.

MAIN FACTS:

-Vashe Wound Therapy is a medical device that produces a biocompatible solution to enhance the clinical management of acute and chronic wounds and has been used successfully and without report of adverse events in more than 100,000 wound treatments.

-The average graft take for Vashe Wound Therapy and 5% Sulfamylon was 97.4% and 96%, respectively. Infection rates during the trial were equivalent, and none were attributable to the therapy.

-The trial showed that Vashe Wound Therapy demonstrated greater than a 50% cost savings compared with 5% Sulfamylon. -By London Bureau, Dow Jones Newswires; Contact Ian Walker; [phone]; [e-mail]

(END) Dow Jones Newswires

November 11, 2009 09:08 ET (14:08 GMT)

Copyright (c) 2009 Dow Jones & Company, Inc.

[joeblogg2] 11/11/2009 14:07

This could be a huge earner!!!

[topinfo] 11/11/2009 14:06

I have posted news.

[21simthy] 11/11/2009 14:06

topinfo/5pongebob again :-))

[topinfo] 11/11/2009 14:01

DJ PuriCore Plc Clinical Results for Vashe Wound Therapy

TIDMPURI

RNS Number : 3542C

PuriCore Plc

11 November 2009

?

PuriCore Announces Promising Clinical Results for Vashe Wound Therapy in Post-Operative Care of Skin Grafts on Burns

Cost-effective biocompatible wound treatment shows potential effectiveness in helping ensure graft take

MALVERN, PENNSYLVANIA, and STAFFORD, UK, 11 November 2009 - PuriCore (LSE: PURI), the life sciences company focused on developing and commercialising proprietary solutions that safely, effectively, and naturally kill infectious pathogens, today announced results of a randomized clinical trial showing the potential effectiveness of its Vashe Wound Therapy in the post-operative care of split-thickness skin grafts for burn injuries. Vashe Wound Therapy is a medical device that produces a biocompatible solution to enhance the clinical management of acute and chronic wounds and has been used successfully and without report of adverse events in more than 100,000 wound treatments. It is a safe, effective, and economical alternative to commonly used wound irrigating solutions that inhibit wound healing.

The clinical trial was conducted by Kevin Foster, MD, MBA, FACS, Co-Director of the Arizona Burn Center at the Maricopa Medical Center in Phoenix, Arizona. Results showed that Vashe Wound Therapy is as effective as the control, 5% Sulfamylon solution (mafenide acetate, USP), a synthetic antimicrobial agent, in the post-operative care of grafts for burns and potentially provides greater pain control. The average graft take for Vashe Wound Therapy and 5% Sulfamylon was 97.4% and 96%, respectively. Infection rates during the trial were equivalent, and none were attributable to the therapy. Further, the trial showed that Vashe Wound Therapy demonstrated greater than a 50% cost savings compared with 5% Sulfamylon. Dr. Foster presented results of this trial at the Southern Regional Burn Conference on November 7, 2009, in Shreveport, LA.

Dr. Foster, lead clinician, said:

"Vashe Wound Therapy is an exciting new alternative technology that demonstrates clinical efficacy for post operative skin graft irrigation while offering significant overall cost savings. This trial also suggests that Vashe has further potential for pain improvement opportunities."

Greg Bosch, Chief Executive, said:

"These clinical results are further evidence that Vashe Wound Therapy is highly effective for wound care, offering an additional boost to the body's own defense and without any cytotoxic effects that can slow the rate of wound healing. With the increasing attention to cost-containment in healthcare, Vashe Wound Therapy offers a new cost-effective alternative to traditional wound irrigants."

About Vashe Wound Therapy

Vashe Wound Therapy is a medical device used for moistening, irrigating, cleaning, and debriding acute and chronic wounds including stage I through IV pressure ulcers, stasis ulcers, diabetic ulcers, post-surgical wounds, first and second degree burns, abrasions, and minor irritations of the skin. Vashe Wound Therapy is biocompatible, non-cytotoxic, and non-mutagenic. Research to date demonstrates that the Vashe Solution provides a safe and effective alternative to cytotoxic products currently used to treat infected wounds and post-operative surgical sites and is an important element in the overall plan of care for effective wound management. It is a cost-effective alternative to traditional wound irrigants and is a non-staining solution.

Enquiries:

+--------------------------+--------------------------+
| Ben Brewerton | Greg Bosch, CEO |
| Susan Quigley | Darren Weiss, CFO |
| Financial Dynamics | PuriCore |
| [phone] | [phone] |
+--------------------------+--------------------------+

About PuriCore

PuriCore (LSE: PURI) is a life sciences company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitization. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficile, E.coli, HIV, Human and Animal Influenza (including H5N1 and H1N1 Influenza), Legionella, MRSA, M.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford and Clevedon, UK.

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.

Vashe and PuriCore are registered trademarks of PuriCore Inc. All other trademarks are property of their respective owners.

This information is provided by RNS

The company news service from the London Stock Exchange

NRACKDKPNBDDADD

(END) Dow Jones Newswires

[bengo2] 11/11/2009 13:51

yes SB a bit of press coverage and we should see the share price up mate :)

[5pongebob] 11/11/2009 13:21

bengo.....did you see the very brief news also...think it came out in the states in the parent company but cant see details about the vashe therapy trials being announced to the market in the UK and the price has not moved....was wondering who had bought 50k....mine are the 2 @7500...lets hope we can be lucky...

[bengo2] 11/11/2009 12:36

just topped up 50K @ 15.98p not even shown, buy or sell

[ian 50] 06/11/2009 00:01

stiff naf all

[arf dysg] 05/11/2009 19:45

Relax. It's a buying opportunity.

[jonnynixon] 05/11/2009 00:54

This is crazy. When are people going to track this share!!

[ian 50] 04/11/2009 23:06

STILL NAF ALL HAPPENING

[bw64402] 03/11/2009 22:34

I bought PURI back in late April with the announcement of Swine Flu. Sold recently as i felt my money was better placed in Gold. So far, this has proved correct as PURI has dropped and my Gold shares soared. I think PURI is a decent business but agree with you JN that the market's not interested. Especially given POG has broken $1080 today and is set to break $1100.

[jonnynixon] 03/11/2009 11:32

A bout time. Looks like puricore is delivering what it set out to this year. News does not seem to be welcomed by the market. Must be a lot of PI saving the pennies for the oil n gas minos and the banks. Guess I need to keep waiting until this bad boy starts to increase share price IMHO this share is undervalued when reading this RNS.

JN

[ian 50] 08/10/2009 02:29

naf all happening at th momment

[jonnynixon] 05/10/2009 20:48

fantastic company guys but whats going on behind the scenes? anyone care to speculate?

[arf dysg] 05/10/2009 11:10

Just nod if you can hear me.

[idandy] 04/10/2009 14:10

Is there anybody out there ????

[idandy] 27/9/2009 22:34

This BB has gone very quiet - Is there nothing going on with PURI at the moment - Is there any news due ?
I would like to see these move up for me........

[ian 50] 11/9/2009 20:04

has anyone been watching this sh/pr its all over the place ive during the last few weeks .luckly up t end of this week.

[arf dysg] 25/8/2009 14:02

Yes, other sites have the announcement, as Piedro has just said.

[piedro] 25/8/2009 13:59

RNS Number : 9343X
PuriCore Plc
25 August 2009
PuriCore Interim Results for the Six Months Ended 30 June 2009

[demac] 25/8/2009 13:23

Arf,

W
hat has Money to say,please